CN101389343B - 抗癌用阿霉素制剂 - Google Patents

抗癌用阿霉素制剂 Download PDF

Info

Publication number
CN101389343B
CN101389343B CN2007800064317A CN200780006431A CN101389343B CN 101389343 B CN101389343 B CN 101389343B CN 2007800064317 A CN2007800064317 A CN 2007800064317A CN 200780006431 A CN200780006431 A CN 200780006431A CN 101389343 B CN101389343 B CN 101389343B
Authority
CN
China
Prior art keywords
weight
hydrophobic
copolymer
mixture
block copolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800064317A
Other languages
English (en)
Chinese (zh)
Other versions
CN101389343A (zh
Inventor
E·克林斯基
K·帕特勒
G·皮奇纳斯基
V·艾拉霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suofate Caim Pharmaceutical Co ltd
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of CN101389343A publication Critical patent/CN101389343A/zh
Application granted granted Critical
Publication of CN101389343B publication Critical patent/CN101389343B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2007800064317A 2006-02-22 2007-02-08 抗癌用阿霉素制剂 Expired - Fee Related CN101389343B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/359,352 US8148338B2 (en) 2006-02-22 2006-02-22 Doxorubicin formulations for anti-cancer use
US11/359,352 2006-02-22
PCT/CA2007/000182 WO2007095722A1 (en) 2006-02-22 2007-02-08 Doxorubicin formulations for anti-cancer use

Publications (2)

Publication Number Publication Date
CN101389343A CN101389343A (zh) 2009-03-18
CN101389343B true CN101389343B (zh) 2012-08-22

Family

ID=38428501

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800064317A Expired - Fee Related CN101389343B (zh) 2006-02-22 2007-02-08 抗癌用阿霉素制剂

Country Status (7)

Country Link
US (1) US8148338B2 (https=)
EP (1) EP1991239B1 (https=)
JP (1) JP5449784B2 (https=)
KR (1) KR101074430B1 (https=)
CN (1) CN101389343B (https=)
CA (1) CA2640997C (https=)
WO (1) WO2007095722A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US20130150311A1 (en) * 2011-12-13 2013-06-13 Grzegorz Pietrzynski Mixed poloxamer excipients
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
EP2716291B1 (en) * 2012-10-08 2019-11-27 Universität Ulm Combination of opioids and anticancer drugs for cancer treatment
EP3068364B1 (en) * 2013-11-14 2021-11-03 Metro Biotech NSW Pty Ltd Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
JP6875285B2 (ja) 2015-03-13 2021-05-19 コーニング インコーポレイテッド エッジ強度試験方法および装置
CA2984379C (en) 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US6387406B1 (en) * 1992-10-08 2002-05-14 Supratek Pharma Inc. Copolymer compositions for oral delivery
US20050119193A1 (en) * 2002-06-03 2005-06-02 Jun Motoyama Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US6387406B1 (en) * 1992-10-08 2002-05-14 Supratek Pharma Inc. Copolymer compositions for oral delivery
US20050119193A1 (en) * 2002-06-03 2005-06-02 Jun Motoyama Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same

Also Published As

Publication number Publication date
EP1991239B1 (en) 2014-09-17
HK1130661A1 (en) 2010-01-08
JP5449784B2 (ja) 2014-03-19
US20070196493A1 (en) 2007-08-23
KR20080110755A (ko) 2008-12-19
KR101074430B1 (ko) 2011-10-17
CA2640997C (en) 2013-11-19
CA2640997A1 (en) 2007-08-30
CN101389343A (zh) 2009-03-18
EP1991239A1 (en) 2008-11-19
JP2009527505A (ja) 2009-07-30
WO2007095722A1 (en) 2007-08-30
US8148338B2 (en) 2012-04-03
EP1991239A4 (en) 2012-09-19

Similar Documents

Publication Publication Date Title
CN101389343B (zh) 抗癌用阿霉素制剂
JP4077794B2 (ja) 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法
CN108136217B (zh) 用于治疗膀胱癌的制剂
CZ20002834A3 (cs) Farmaceutický prostředek
JP6159567B2 (ja) 既製のゲムシタビン注入溶液
US20170071976A1 (en) Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same
CN103550233A (zh) 使用血管加压素拮抗剂与蒽环类化疗试剂以减少心脏中毒和/或提高存活率的方法
CN116600788B (zh) 盐酸米托蒽醌脂质体的用途
WO2025098138A1 (zh) 一种荧光-磁共振双模态造影剂及其制备方法
US20250352535A1 (en) Mdm2 degraders and uses thereof
Li et al. Cysteine-modified PEGylated nanoparticles for targeted delivery of methylprednisolone to pancreatitis
JP2019513123A (ja) 凍結医薬製剤およびその使用
US11304898B2 (en) Method of treating carcinoma
WO2021208842A1 (zh) 盐酸米托蒽醌脂质体的用途
CN104546722B (zh) 米铂脂质体和制法
HK1130661B (en) Doxorubicin formulations for anti-cancer use
RU2623142C2 (ru) Внутрипузырное введение апазиквона после трансуретральной резекции при лечении рака
RU2821033C1 (ru) Раствор аминодигидрофталазиндиона натрия для внутривенного введения
CN115414491B (zh) 一种用于治疗宫颈癌的药物及其制备方法
RU2784869C1 (ru) Чиаураниб для лечения мелкоклеточного рака легкого
CN104470500A (zh) 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物
TW201817416A (zh) 用於治療膀胱癌之配方
HK1255212B (zh) 用於治疗膀胱癌的制剂
BR102017020068A2 (pt) Micelas poliméricas carregadas do fármaco miltefosina e produto para o tratamento do cancer e doenças infecciosas

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130661

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1130661

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20171121

Address after: Quebec

Patentee after: Suofate Caim Pharmaceutical Co.,Ltd.

Address before: Quebec

Patentee before: Supratek Pharma Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

CF01 Termination of patent right due to non-payment of annual fee